Author： Higby K.
Publisher： Adis International
ISSN： 0114-5916
Source： Drug Safety, Vol.21, Iss.1, 1999-07, pp. : 35-56
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
A Risk-Benefit Assessment of Pharmacological Therapies for Hirsutism
By Carmina E.
Drug Safety, Vol. 24, Iss. 4, 2001-01 ,pp. :
Access to resources
Recommend
A Risk-Benefit Assessment of Therapies for Lennox-Gastaut Syndrome
By Schmidt D.
Drug Safety, Vol. 22, Iss. 6, 2000-06 ,pp. :
Risk-Benefit Assessment of Therapies for Mycobacterium avium Complex Infections
Drug Safety, Vol. 21, Iss. 2, 1999-08 ,pp. :
A Risk-Benefit Assessment of Abciximab in Angioplasty
By Kleiman N.S.
Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. :
A Risk-Benefit Assessment of Amifostine in Cytoprotection
By Mabro M.
Drug Safety, Vol. 21, Iss. 5, 1999-11 ,pp. :